These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

672 related items for PubMed ID: 31446020

  • 1. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
    Fukihara J, Sakamoto K, Koyama J, Ito T, Iwano S, Morise M, Ogawa M, Kondoh Y, Kimura T, Hashimoto N, Hasegawa Y.
    Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
    Ksienski D, Wai ES, Croteau N, Fiorino L, Brooks E, Poonja Z, Fenton D, Geller G, Glick D, Lesperance M.
    Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
    Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, Grassadonia A, Di Marino P, Tinari N, De Tursi M, Zoratto F, Veltri E, Malorgio F, Garufi C, Russano M, Anesi C, Zeppola T, Filetti M, Marchetti P, Berardi R, Rinaldi S, Tudini M, Silva RR, Pireddu A, Atzori F, Iacono D, Migliorino MR, Porzio G, Cannita K, Ficorella C, Buti S.
    Clin Lung Cancer; 2019 Jul; 20(4):237-247.e1. PubMed ID: 30885550
    [Abstract] [Full Text] [Related]

  • 5. Relationship Between Prior Radiotherapy and Checkpoint-Inhibitor Pneumonitis in Patients With Advanced Non-Small-Cell Lung Cancer.
    Voong KR, Hazell SZ, Fu W, Hu C, Lin CT, Ding K, Suresh K, Hayman J, Hales RK, Alfaifi S, Marrone KA, Levy B, Hann CL, Ettinger DS, Feliciano JL, Peterson V, Kelly RJ, Brahmer JR, Forde PM, Naidoo J.
    Clin Lung Cancer; 2019 Jul; 20(4):e470-e479. PubMed ID: 31031204
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.
    Inoue T, Tamiya M, Tamiya A, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Kunimasa K, Kimura M, Suzuki H, Hirashima T, Atagi S, Imamura F.
    Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab.
    Oyanagi J, Koh Y, Sato K, Mori K, Teraoka S, Akamatsu H, Kanai K, Hayata A, Tokudome N, Akamatsu K, Nakanishi M, Ueda H, Yamamoto N.
    Lung Cancer; 2019 Jun; 132():107-113. PubMed ID: 31097082
    [Abstract] [Full Text] [Related]

  • 10. Association of immune-related pneumonitis with clinical benefit of anti-programmed cell death-1 monotherapy in advanced non-small cell lung cancer.
    Ono K, Ono H, Toi Y, Sugisaka J, Aso M, Saito R, Kawana S, Aiba T, Odaka T, Matsuda S, Saito S, Narumi A, Ogasawara T, Shimizu H, Domeki Y, Terayama K, Kawashima Y, Nakamura A, Yamanda S, Kimura Y, Honda Y, Sugawara S.
    Cancer Med; 2021 Jul; 10(14):4796-4804. PubMed ID: 34121358
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study.
    Fujimoto D, Yoshioka H, Kataoka Y, Morimoto T, Kim YH, Tomii K, Ishida T, Hirabayashi M, Hara S, Ishitoko M, Fukuda Y, Hwang MH, Sakai N, Fukui M, Nakaji H, Morita M, Mio T, Yasuda T, Sugita T, Hirai T.
    Lung Cancer; 2018 May; 119():14-20. PubMed ID: 29656747
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
    Yin B, Xiao J, Li J, Liu X, Wang J.
    J Cancer Res Ther; 2020 May; 16(7):1555-1559. PubMed ID: 33565499
    [Abstract] [Full Text] [Related]

  • 15. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A, Calvetti L, Dal Maso A, Attili I, Del Bianco P, Pasello G, Guarneri V, Aprile G, Conte P, Bonanno L.
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [Abstract] [Full Text] [Related]

  • 16. Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.
    Hammer M, Bagley S, Aggarwal C, Bauml J, Nachiappan AC, Simone CB, Langer C, Katz SI.
    Curr Probl Diagn Radiol; 2019 Aug; 48(2):142-147. PubMed ID: 29573843
    [Abstract] [Full Text] [Related]

  • 17. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.
    Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, Arranz R, Lorenzo A, Gullón P, Donnay O, Adrados M, Costas P, Aspa J, Alfranca A, Mondéjar R, Colomer R.
    Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533
    [Abstract] [Full Text] [Related]

  • 18. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
    Zhou Y, Xia R, Xiao H, Pu D, Long Y, Ding Z, Liu J, Ma X.
    Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
    [Abstract] [Full Text] [Related]

  • 19. Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis.
    Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Yatabe Y, Hida T.
    Lung Cancer; 2018 Nov; 125():212-217. PubMed ID: 30429022
    [Abstract] [Full Text] [Related]

  • 20. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K, Uchida N, Kanai O, Okamura M, Nakatani K, Mio T.
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.